Luma Healthcare, Inc.

Aegle Therapeutics | October 06, 2020

Aegle Therapeutics Corporation, a first-in-class biotechnology company committed to delivering cell-free therapy to patients affected by severe dermatological conditions, today announced that the FDA has granted Rare Pediatric Disease (RPD) Designation to AGLE-102™ for the treatment of dystrophic epidermolysis bullosa (DEB), a skin blistering disorder. AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerat...

Genetic Engineering and Biotechnology News | April 24, 2020

Investigators at the German Cancer Research Center in Heidelberg (DKFZ) and the Mannheim Medical Faculty of the University of Heidelberg have released data on an antibody they created that blocks a receptor that stimulates the formation of new blood vessels in tumors and metastasis. Findings from the new stud—published recently in EMBO Molecular Medicine through an article entitled “Preclinical validation of a novel metastasis‐inhibiting Tie1 function‐blocking antibody”—s...

CELL AND GENE THERAPY

PDS Biotechnology Corporation | December 27, 2021

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS ...

INDUSTRIAL IMPACT

AbCellera and Atlas Venture | August 04, 2022

AbCellera and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas’ proven track record in forming innovative biotechnology companies and AbCellera’s unique ability to quickly deliver lead drug candidates to bring transformational new medicines to patients faster. "Ab...